GLP-2 & Teduglutide: Gut-Health Research Peptide Guide

GLP-2 is a 33-amino-acid peptide cleaved from proglucagon in enteroendocrine L-cells of the distal small intestine and colon — the same precursor that yields GLP-1. It is released after nutrient intake and acts on the GLP-2 receptor, a class B G-protein-coupled receptor expressed on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells rather than on enterocytes directly. Signalling is therefore indirect, mediated through IGF-1, ErbB ligands and nitric-oxide pathways.

Native GLP-2 is degraded within minutes by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal dipeptide. Teduglutide substitutes alanine at position 2 with glycine ([Gly2]GLP-2), which resists DPP-4 cleavage and extends the circulating half-life from roughly 7 minutes to several hours. That single substitution is what makes the molecule usable as an experimental reference standard rather than a laboratory curiosity.

Both peptides come from proglucagon and both are released after eating, but their receptors and downstream literature diverge almost completely. GLP-1 research looks at insulin secretion, gastric emptying and appetite signalling — the pathway behind semaglutide, tirzepatide and retatrutide. GLP-2 research looks at mucosal growth: crypt cell proliferation, reduced enterocyte apoptosis, increased villus surface area, mesenteric blood flow and tight-junction expression.

In practical terms, a researcher comparing GLP-1 and GLP-2 material is comparing metabolic endpoints against gastrointestinal-barrier endpoints. The two are not interchangeable, and protocols written for one do not transfer to the other.

Teduglutide is the most-studied GLP-2 analogue, with published clinical work in short bowel syndrome showing increased intestinal absorptive capacity and reduced parenteral support requirements. Preclinical models report increased villus height, deeper crypts and improved barrier function after GLP-2 receptor agonism.

Beyond that indication, GLP-2 appears in exploratory literature on intestinal barrier permeability, chemotherapy-induced mucositis models and inflammatory bowel disease models. Those datasets are preclinical or early-phase; they describe mechanism, not established outcomes. Anyone reading GLP-2 material should keep the distinction between an approved indication and an exploratory model firmly in view.

Treat GLP-2 analogue reference material like any lyophilised research peptide: keep sealed vials at 2–8 °C and out of light, reconstitute with bacteriostatic water added down the inner wall of the vial, swirl rather than shake, and label with date, concentration and lot number. Sealed 10-vial kits held in cold storage stay stable for roughly 8–12 months; once reconstituted, expect around 2 months of refrigerated in-use stability at 2–8 °C. The lot-matched COA always overrides a general rule of thumb.

Confirm four things before accepting a batch: HPLC purity with the chromatogram attached (not just a stated percentage), mass-spectrometry identity confirmation matching the expected molecular weight for the [Gly2]GLP-2 sequence, peptide content by nitrogen or amino-acid analysis so you know the actual peptide mass in the vial, and a lot number that matches the vial label. Regena publishes independent third-party reports in the COA library so the batch you receive is the batch you can read about.

GLP-2 work is dose- and duration-sensitive because the endpoint is tissue remodelling rather than an acute signal, so studies typically run over days to weeks rather than hours. Plan vial count against study length before ordering — Regena supplies research peptides in 10-vial kits of a single compound, which typically covers an 8–12 month research cycle. If you are unsure which reference compounds fit a gut-barrier protocol, the catalogue and a short consultation are the fastest route.